Skip to main content
. 2022 Mar 1;132(5):e141797. doi: 10.1172/JCI141797

Figure 10. SIRPγ-neutralizing antibody targets both CSLCs and immune evasion to inhibit tumor growth in vitro and in vivo.

Figure 10

(A) Phagocytosis of A549 cells with or without anti-SIRPγ LSB2.20 or anti–IGF-1R antibody treatment (4 μg/mL, 6 hours). (B) Strategy of LSB2.20 treatment of A549 tumor xenografts in female nude mice (n = 5 per group). (C and D) LSB2.20 inhibits A549 xenograft growth (C) and reduces the xenograft weight (D). (E and F) LSB2.20 promotes phagocytosis in A549 xenografts, represented by the enhanced percentage of GFP+F4/80+CD11b+ cells in total F4/80+CD11b+ cells. (G) The ratio of human DNA to mouse DNA in sorted tumor macrophages. All experiments were carried out at least in triplicate and the data are presented as the mean ± SD. *P < 0.05; **P < 0.01 by 1-way ANOVA.